Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2022-04-19 Earnings Release
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document explicitly states: "ADOCIA annonce ses résultats annuels 2021 et présente un bilan de ses activités" (ADOCIA announces its 2021 annual results and presents a review of its activities). It contains a detailed table summarizing consolidated annual accounts established under IFRS for the fiscal years ending December 31, 2021, and 2020, including revenue, operating expenses, and net result. This content structure, covering a full fiscal year's performance with detailed financial tables, strongly indicates an Annual Report or a document closely associated with it. Since the text provides the full financial results and a comprehensive review of the year's activities, it aligns best with the Annual Report category (10-K), even if it might be a press release version of the annual results rather than the formal SEC 10-K filing itself. Given the options, '10-K' is the most appropriate classification for a comprehensive annual financial results announcement. FY 2021
2022-04-19 French
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information relative au nombre d'actions et de droits de vote en date du 31 mars 2022" and explicitly references compliance with French regulations (Article L.233-8 II du Code de Commerce and Article 223-16 du Règlement Général de l'AMF). It provides a table detailing the total number of shares and voting rights (BRUT and NET) as of a specific date (March 31, 2022). This type of mandatory disclosure regarding the total share capital and voting rights is a specific regulatory filing requirement, often related to major shareholding notifications or general capital structure updates, but it is a distinct periodic disclosure. Given the options, this is a specific regulatory announcement concerning capital structure/shareholder rights, which is not explicitly covered by the main financial reports (10-K, IR, ER). It is most closely related to changes in share structure or major ownership thresholds. Since it is a formal, periodic disclosure of share count mandated by the AMF, and it is not a general earnings release, management discussion, or a proxy statement, it fits best under the category for notifications about share changes or major holdings. However, the core content is the official count of shares and voting rights. This is a specific type of regulatory filing. Comparing the definitions, it is not a Director's Dealing (DIRS), nor a general Major Shareholding Notification (MRQ) which usually reports a change crossing a threshold, but rather a mandatory periodic update of the total count. Since it is a formal, required disclosure that doesn't fit the primary financial reports, it falls under the general regulatory announcement category, RNS, or potentially SHA (Share Issue/Capital Change) if interpreted broadly. Given the focus on the total number of shares and voting rights, which is a fundamental capital structure metric reported periodically, SHA is a strong candidate, but RNS is the safest fallback for specific, non-standard regulatory updates. Let's re-evaluate: The document reports the total number of shares and voting rights, which is a prerequisite for tracking major shareholdings (MRQ) or general capital changes (SHA). Since it is a mandatory disclosure of the total capital base, it is a fundamental regulatory filing. In the context of the provided codes, it is a specific regulatory disclosure. It is not a proxy, dividend, or earnings report. It is a formal notification about the capital structure. SHA (Share Issue/Capital Change) covers changes to the capital structure. While this is a periodic report of the *current* structure, it is triggered by capital events (like the convertible bond conversion mentioned). I will classify this as a specific regulatory filing (RNS) as it is a mandatory AMF disclosure that doesn't perfectly align with the other specific financial report types, although it touches upon capital structure.
2022-04-15 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document explicitly states its purpose: to release the 'total number of outstanding shares as well as its voting rights as of March 31st, 2022,' pursuant to French regulatory requirements (Code de Commerce and AMF charter). This type of mandatory disclosure regarding share capital structure and voting rights is a specific regulatory filing. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). While it relates to capital structure, it is a mandatory regulatory disclosure about share count, which fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Share Capital Disclosure' outside of general transaction reports (SHA/POS). However, given the context of mandatory disclosure of shareholding thresholds (Article L. 233-8 II), this is a specific type of regulatory filing. Since the provided list does not have a specific code for 'Total Shares Outstanding Disclosure', RNS is the most appropriate fallback for a mandatory regulatory announcement that isn't one of the other specific types. It is not a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ), as it is the company reporting its total count, not an individual crossing a threshold.
2022-04-15 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing the start of three clinical studies for a drug candidate (BioChaperone® Combo) and detailing a partnership agreement with Tonghua Dongbao, including financial terms (milestones and royalties). It provides key operational and financial updates but is not a comprehensive annual report (10-K), a formal quarterly report (IR), or a transcript of a call (CT). It is an announcement of business progress and partnership details. Since it is a press release announcing significant business developments, it fits best under the general category of a Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but RNS serves as the best general regulatory announcement fallback for non-standard reports. Given the content is a news announcement about clinical progress and partnership milestones, RNS is the most appropriate general classification for this type of corporate disclosure that isn't a specific financial report.
2022-04-11 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Adocia announcing the launch of three clinical studies for its BioChaperone® Combo product in partnership with Tonghua Dongbao. It details scientific progress, financial terms of the agreement (milestones and royalties), and provides company background information. This type of announcement, focusing on operational and strategic developments (clinical trials, partnerships, financial milestones) rather than routine periodic financial results (like 10-K or IR) or mandatory regulatory filings (like DIRS or DEF 14A), fits best under the general category of corporate news or updates. Since it is not a formal Earnings Release (ER), Interim Report (IR), or a specific transaction notice (like CAP or TAR), and it is a substantial announcement detailing business progress, it is classified as a general Regulatory Filing (RNS) as a broad category for corporate news releases that don't fit the highly specific codes, although it shares characteristics with an Investor Presentation (IP) or Management Discussion (MDA) in content depth. Given the options, RNS serves as the most appropriate catch-all for significant, non-standard corporate announcements, though 'LTR' (Legal Proceedings Report) or 'CAP' (Capital/Financing Update, due to the milestone payments) are less fitting. Since it is a press release announcing operational progress, RNS is the best fit among the provided codes for a general corporate update.
2022-04-11 French
Inside Information / Other news releases
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a specific corporate action: the sale of a building in a sale-and-leaseback transaction, resulting in a cash inflow of 19 million euros. It details the financial impact and strategic rationale. This type of announcement, focusing on a significant, non-routine financial event (like a major asset sale or financing activity), fits best under the 'Capital/Financing Update' category (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER) focusing on operational results, or a standard regulatory filing (RNS) without a more specific category. Since it directly concerns strengthening the cash position via a major transaction, CAP is the most appropriate classification.
2022-03-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.